innovair nexthaler 100+6 mikrog./dosis inhalationspulver
chiesi farmaceutici s.p.a. - beclometasondipropionat, formoterolfumarat dihydrat - inhalationspulver - 100+6 mikrog./dosis
lynetoril 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
chiesi pharmaceuticals gmbh - bendamustinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
lamzede
chiesi farmaceutici s.p.a. - velmanase alfa - alpha-mannosidosis - andre alimentary tract and metabolism produkter, - behandling af ikke-neurologiske forstyrrelser hos patienter med mild til moderat alpha-mannosidosis.
trydonis
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - vedligeholdelsesbehandling hos voksne patienter med moderat til svær kronisk obstruktiv lungesygdom (kol), der ikke er tilstrækkeligt behandlet ved en kombination af et inhaleret binyrebarkhormon og en langtidsvirkende beta2-agonist (for effekter på symptomer kontrol og forebyggelse af eksacerbationer se afsnit 5.
innovair nexthaler 200+6 mikrog./dosis inhalationspulver
chiesi farmaceutici s.p.a. - beclometasondipropionat, formoterolfumarat dihydrat - inhalationspulver - 200+6 mikrog./dosis
elfabrio
chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry disease - andre alimentary tract and metabolism produkter, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).
quinsair
chiesi farmaceutici s.p.a - levofloxacin - cystic fibrosis; respiratory tract infections - antibakterielle midler til systemisk brug, - quinsair er indiceret til management af kronisk pulmonal infektioner på grund af pseudomonas aeruginosa hos voksne patienter med cystisk fibrose. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
innovair nexthaler 200+12 mikrog./dosis inhalationspulver
chiesi farmaceutici s.p.a. - beclometasondipropionat, formoterolfumarat dihydrat - inhalationspulver - 200+12 mikrog./dosis
bramitob 300 mg/4 ml inhalationsvæske til nebulisator, opløsning
chiesi farmaceutici s.p.a. - tobramycin - inhalationsvæske til nebulisator, opløsning - 300 mg/4 ml